Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 11, 2012, Pages 2336-2342

  Simioni, C ^a   Neri, L M ^a   Tabellini, G ^b   Ricci, F ^c   Bressanin, D ^d   Chiarini, F ^e   Evangelisti, C ^e   Cani, A ^a   Tazzari, P L ^c   Melchionda, F ^d   Pagliaro, P ^c   Pession, A ^d   McCubrey, J A ^f   Capitani, S ^a   Martelli, A M ^d,e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^f EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Akt; Autophagy; Chemotherapy; T cell acute lymphoblastic leukemia; Targeted therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; PROTEIN KINASE B;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE; DOXORUBICIN; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PHOSPHORYLATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84869086211     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.136     Document Type: Article

References (41)

1. Cardoso BA, de Almeida SF, Laranjeira AB, Carmo-Fonseca M, Yunes JA, Coffer PJ et al. TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 1578-1586.
2. Mansur MB, Ford AM, van Delft FW, Gonzalez D, Emerenciano M, Maia RC et al. Occurrence of identical NOTCH1 mutation in non-twinned sisters with T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 1368-1370.
3. Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011; 25: 588-598.
4. Sulis ML, Saftig P, Ferrando AA. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia 2011; 25: 1564-1569.
5. Yu L, Slovak ML, Mannoor K, Chen C, Hunger SP, Carroll AJ et al. Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 1042-1046.
6. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043. (Pubitemid 351389536)
7. Demarest RM, Ratti F, Capobianco AJ. It's T-ALL about Notch. Oncogene 2008; 27: 5082-5091.
8. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064-1079.
9. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006; 25: 7381-7390. (Pubitemid 44853429)
10. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G et al. The miRNA-17B92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012; 26: 1064-1072.
11. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-717.
12. Wang P, Zhang L, Hao Q, Zhao G. Developments in selective small molecule ATPtargeting the serine/threonine kinase Akt/PKB. Mini Rev Med Chem 2011; 11: 1093-1107.
13. Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: Implications for therapeutic strategies in leukemia. Blood 2012; 119: 911-923.
14. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
15. Zhao WL. Targeted therapy in T-cell malignancies: Dysregulation of the cellular signaling pathways. Leukemia 2010; 24: 13-21.
16. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115: 1406-1415.
17. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 2010; 18: 353-366.
18. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27: 5511-5526.
19. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
20. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2011; 11: 154-164.
21. Tan S, Ng Y, James DE. Next-generation Akt inhibitors provide greater specificity: Effects on glucose metabolism in adipocytes. Biochem J 2011; 435: 539-544.
22. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
23. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-791.
24. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147-160.
25. Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 2010; 24: 687-698.
26. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22: 1106-1116. (Pubitemid 351833776)
27. Nyakern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006; 5: 1559-1570. (Pubitemid 44070493)
28. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M et al. AMPdependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: Therapeutic implications. Leukemia 2012; 26: 91-100.
29. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2012; 23: 744-755.
30. Gordy C, He YW. The crosstalk between autophagy and apoptosis: Where does this lead? Protein Cell 2012; 3: 17-27.
31. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S et al. Long-term followup results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801. (Pubitemid 39603187)
32. Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011; 51: 37-49.
33. Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 960-967.
34. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007; 109: 674-682. (Pubitemid 46105969)
35. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009; 69: 3520-3528.
36. Laplante M, Sabatini DM. mTOR Signaling in growth control and disease. Cell 2012; 149: 274-293.
37. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-1295.
38. Liang C. Negative regulation of autophagy. Cell Death Differ 2010; 17: 1807-1815.
39. Levine B, Kroemer G. Autophagy in aging, disease and death: The true identity of a cell death impostor. Cell Death Differ 2009; 16: 1-2.
40. Meuillet EJ. Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem 2011; 18: 2727-2742.
41. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: The Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.